Myriad Genetics Inc.

A petition recently filed with the Supreme Court triggers renewed debate about the role of patents in the diagnostics sector.

David Schwartz of the Illinois Institute of Technology-Chicago, Kent College of Law, discusses the impact of the US Supreme Court unanimously striking down Myriad Genetics' patent of human BRCA genes and tests to detect mutations in them.

The Utah-based firm has settled its lawsuit claiming patent infringement against Pathway Genomics.

A genetic testing firm accused of infringing upon Myriad Genetics’s gene patents fights back in an attempt to wipe other patents out.

A judge declines Myriad Genetics’s request to block its competitors from selling BRCA tests.  

Kerry Grens looks back at the biggest science stories in 2013

How the US government impacted life science research in 2013

Myriad Genetics, the company originally behind tests for the cancer-associated BRCA mutations, is suing two competitors for patent infringement.

Myriad Genetics can hold patents on the BRAC1 and BRAC2 oncogenes, but not on tests comparing DNA sequences.

A public interest legal group has renewed the fight against DNA patenting.

The US Supreme Court ordered patents held by Myriad Genetics to be reviewed further by the Federal Circuit Court.